Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesEndo International PLC

Endo International PLC

PortfolioPortfolio WatchlistWatchlist
Company price
None GBX 0.00(0%)
Last update at 2026-10-28T03:30:11.996293Z
Market Cap
9.90M

Momentum Score

…

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company offers branded pharmaceuticals, including XIAFLEX to treat adult patients with Dupuytren's contracture and Peyronie's disease; SUPPRELIN LA to treat central precocious puberty in children; AVEED to treat hypogonadism; NASCOBAL nasal spray to treat vitamin B12 deficiency; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET for pain management; TESTOPEL, an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; and EDEX to treat erectile dysfunction, as well as opioid products to treat pain associated with post-herpetic neuralgia. It also provides ADRENALIN, a non-selective adrenergic agonist to treat anaphylaxis; VASOSTRICT, a vasopressin IV solution; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products. In addition, the company offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. Further, it provides specialty pharmaceutical products and over-the-counter products. The company sells its products to specialty physicians, wholesale distributors, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
672.84
Low
1068.56
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1076.28
Dividend Yield
-
Revenue TTM
2011.52M
Revenue Per Share
8.55
Gross Profit TTM
1288.18M
Debt / Equity
-0.00
ROE
-
Net Debt
-939.15M
ROCE
-51.99%
Diluted EPS TTM
-3.11

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -2391.92M -2888.10M -546.60M -26.52M -344.90M
Net income -2449.81M -2909.62M -569.08M 247.46M -360.58M
Selling general administrative 469.53M 646.56M 704.17M 594.65M 569.32M
Selling and marketing expenses 98.20M 130.40M 136.80M 76.00M 63.10M
Gross profit 1069.62M 1288.18M 1781.20M 1513.86M 1345.03M
Ebit -2390.93M 386.29M 818.15M 722.73M 581.87M
Ebitda -2084.49M 441.41M 1250.54M 1219.08M 1194.74M
Depreciation and amortization 306.45M 55.12M 432.38M 496.35M 612.86M
Operating income 386.43M 386.29M 818.15M 722.73M 581.87M
Other operating expenses 1625.09M 4857.20M 2977.46M 2396.65M 2720.53M
Interest expense 0.99M - 0.00M 0.00M 0.00M
Tax provision - - - -144.38M 15.68M
Interest income - - - 533.25M 546.33M
Extraordinary items - - - 66.08M -62.05M
Income tax expense 55.86M 21.52M 22.48M 273.98M 15.68M
Total revenue 2011.52M 2318.88M 2993.21M 2903.07M 2914.36M
Total operating expenses 683.19M 3826.51M 1765.45M 1007.44M 1151.20M
Cost of revenue 941.90M 1030.69M 1212.01M 1389.21M 1569.34M
Total other income expense net -2778.35M -3274.39M -1364.76M -749.25M -926.78M
Discontinued operations - -13.49M -44.16M -63.52M -62.05M
Net income applicable to common shares - -2923.11M -613.25M 183.94M -422.64M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 5137.29M 5757.94M 8767.42M 9264.64M 9389.53M
Intangible assets 1477.88M 1732.93M 2362.82M 2740.81M 2571.27M
Other current assets 80.06M 287.90M 329.02M 333.10M 335.87M
Total liab 11734.85M 9920.11M 10011.40M 9912.58M 10256.07M
Total stockholder equity -6597.56M -4162.17M -1243.99M -647.94M -866.54M
Other current liab 442.40M 803.77M 1506.83M 1159.42M 1358.76M
Common stock 0.07M 0.02M 0.02M 0.02M 0.02M
Retained earnings -15354.43M -12904.62M -9981.51M -9368.27M -9552.21M
Other liab - 1152.85M 280.36M 315.01M 356.27M
Good will 1352.01M 1352.01M 3197.01M 3560.01M 3595.18M
Other assets 0.00M 129.84M 61.45M 55.06M 80.29M
Cash 945.62M 1018.88M 1507.20M 1213.44M 1454.53M
Total current liabilities 538.79M 943.12M 1629.96M 1253.82M 1460.29M
Current deferred revenue 0.60M - - - -
Net debt -939.15M -1018.88M -1507.20M -1213.44M -1454.53M
Short term debt 0.96M - - - -
Short long term debt total 6.47M - - 8305.60M 8391.21M
Other stockholder equity 8980.56M 8742.42M 8737.51M 8720.31M 8685.65M
Property plant equipment - 466.38M 431.54M 495.50M 556.57M
Total current assets 1668.50M 2076.77M 2714.59M 2413.26M 2586.22M
Net tangible assets - -7247.12M -6803.82M -6948.76M -7032.99M
Net receivables 396.80M 495.49M 594.82M 514.46M 467.95M
Long term debt - - - 8280.58M 8359.90M
Inventory 246.02M 274.50M 283.55M 352.26M 327.87M
Accounts payable 94.73M 139.35M 123.13M 94.41M 101.53M
Accumulated other comprehensive income -223.76M - - - -
Non currrent assets other -1432.54M -3551.33M -5991.38M -6796.32M -6723.02M
Non current assets total 3468.79M 3551.33M 5991.38M 6796.32M 6723.02M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments - - - 92.76M 92.76M
Change to liabilities - 321.06M 84.39M -171.37M -525.75M
Total cashflows from investing activities -49.79M -133.15M -59.54M -624.87M -60.20M
Net borrowings - -509.51M -78.75M -96.68M 237.99M
Total cash from financing activities -604.63M -513.87M -105.48M -108.57M 204.60M
Change to operating activities - 80.35M -34.00M -27.42M 11.37M
Net income -2447.79M -2923.11M -613.25M 183.94M -422.64M
Change in cash -218.62M -382.07M 246.31M -335.39M 243.55M
Begin period cash flow 1164.24M 1631.31M 1385.00M 1720.39M 1476.84M
End period cash flow 945.62M 1249.24M 1631.31M 1385.00M 1720.39M
Total cash from operating activities 435.10M 269.19M 411.05M 402.12M 98.05M
Depreciation 306.45M 55.12M 432.38M 496.35M 612.86M
Other cashflows from investing activities 39.40M 18.64M -6.90M -6.90M 0.91M
Change to inventory 22.20M -4.36M 48.98M -8.03M -27.14M
Change to account receivables 106.51M 105.91M -82.05M -45.79M 19.16M
Sale purchase of stock - -1.90M -14.77M -8.04M -10.16M
Other cashflows from financing activities -604.63M -2.46M 3248.02M -3.85M 1759.89M
Change to netincome - 2291.43M 467.43M 26.75M 407.37M
Capital expenditures 94.33M 102.86M 80.65M 72.86M 67.69M
Change in working capital 1664.79M 101.55M -33.07M -53.82M -7.98M
Stock based compensation 11.24M 18.21M 30.05M 41.36M 59.14M
Other non cash items -108.95M 3017.41M 594.94M -265.71M -143.34M
Free cash flow 340.77M 166.33M 330.40M 329.26M 30.36M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
0R15
SoftBank Group Corp.		 248.00
5.84%		 4494.00 - - - -
0R1E
Nintendo Co. Ltd.		 -115.00
1.34%		 8476.00 - - - -
0LC3
Synchrony Financial		 2.34
3.20%		 75.60 0.09 - 4.97 -
0HQP
CBRE Group Inc. Cl A		 0.15
0.12%		 122.47 0.25 - 1.18 -

Profile*

Endo International PLC

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company offers branded pharmaceuticals, including XIAFLEX to treat adult patients with Dupuytren's contracture and Peyronie's disease; SUPPRELIN LA to treat central precocious puberty in children; AVEED to treat hypogonadism; NASCOBAL nasal spray to treat vitamin B12 deficiency; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET for pain management; TESTOPEL, an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; and EDEX to treat erectile dysfunction, as well as opioid products to treat pain associated with post-herpetic neuralgia. It also provides ADRENALIN, a non-selective adrenergic agonist to treat anaphylaxis; VASOSTRICT, a vasopressin IV solution; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products. In addition, the company offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. Further, it provides specialty pharmaceutical products and over-the-counter products. The company sells its products to specialty physicians, wholesale distributors, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Minerva House, Dublin, Ireland, 4

353 1 268 2000

https://www.endo.com

2931

Name Title Year Born
Mr. Blaise A. Coleman Pres, CEO & Director 1974
Mr. Mark T. Bradley Exec. VP & CFO 1970
Mr. Matthew Joseph Maletta Exec. VP, Chief Legal Officer & Company Sec. 1972
Mr. Patrick A. Barry Exec. VP & Pres of Global Commercial Operations 1968
Frank B. Raciti VP, Controller & Chief Accounting Officer NA
Ms. Cheryl Stouch Sr. VP of Information Technology & Chief Information Officer NA
Ms. Laure E. Park Sr. VP of Investor Relations & Corp. Affairs NA
Ms. Susan Williamson Sr. VP & Chief Compliance Officer NA
Ms. Tracy Basso Chief HR Officer NA
Mr. James Papp Head of Endo Ventures Limited & Sr. VP of Global Supply Chain NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…